Society management

Cytokinetics Announces Upcoming Presentations at the 2022 HCM Society Inaugural Scientific Sessions and HFSA Annual Scientific Meeting

Cytokinetics, Incorporated

Two last-minute clinical trial sessions to showcase new REDWOOD-HCM OLE data

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two at the HCM Society 2022 Inaugural Scientific Sessions hosted by this new professional medical society in National Harbor, MD, on September 30, 2022, and four presentations at the annual scientific meeting of the Heart Failure Society of America (HFSA) to be held in Washington, DC, from September 30, 2022 to October 3, 2022.

New data from REDWOOD-HCM OLE (Randomized Eevaluation of Dto dare Owith CK-274 in Oconstructive Oexit Dis sick in HCM Open LAbel Extension) will be featured in two late-breaking clinical trial presentations, including one at the HCM Society 2022 Scientific Sessions on Withdrawal from Basic Standard Medical Treatment and one at the HFSA Annual Scientific Meeting on Enhancement symptoms.

HCM Society 2022 Scientific Sessions

Last minute clinical trial session

Title: Withdrawal from Basic Medical Treatment Standard of Care in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in REDWOOD-HCM OLE
Presenter: Ahmad Masri, MD, Assistant Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
Date: September 30, 2022
Session title: Last minute tests
session time: 10:30 a.m. – 10:40 a.m. ET
Location: Westin Port National

Poster presentation

Title: Impacts on the quality of life of patients with hypertrophic obstructive cardiomyopathy
Date: September 30, 2022
Location: Westin Port National

HFSA Annual Scientific Meeting

Last minute clinical trial session

Title: Improvement of KCCQ Scores in Patients With Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in the REDWOOD-HCM OLE study
Presenter: Sara Saberi, MD, assistant professor, cardiovascular medicine, Frankel Cardiovascular Center, University of Michigan Health
Date: October 2, 2022
Session title: Last Minute Clinical Trials Session II
session time: 9:45 a.m. – 10:45 a.m. ET
Presentation time: 10:15 a.m. – 10:25 a.m. ET
Location: Potomac A/B

Poster presentations

Title: Efficacy and safety of Aficamten in Patients with Symptomatic Hypertrophic Obstructive Cardiomyopathy: Interim Results from the Randomized Evaluation of CK-3773274 Dosing in the Hypertrophic Cardiomyopathy Open-Label (OLE) Extension Study (REDWOOD-HCM)
Presenter: Ahmad Masri, MD, Assistant Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
Date: October 1, 2022
Session title: Oral Poster Session II
poster number: 352
session time: 12:00 p.m. – 1:00 p.m. ET
Location: Exhibition hall, oral poster theater

Title: Safety, efficacy and quantitative understanding of obstruction, impact of Aficamten in hypertrophic cardiomyopathy (SEQUOIA-HCM) Study design: a phase 3 study
Presenter: Caroline Coats, Ph.D., Clinical Lecturer, School of Cardiovascular and Metabolic Health, University of Glasgow
Date: October 1, 2022
Session title: General Poster Viewing Session II
poster number: CTC-001
session time: 12:45 p.m. – 1:00 p.m. ET
Location: Exhibition Hall ePoster Hub, Monitor 3

Title: Prevalence and excess risk of hospitalization in heart failure with reduced ejection fraction
Presenter: Nihar R. Desai, MD, MPH, Associate Professor of Medicine, Associate Chief, Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and Evaluation
Date: October 1, 2022
Session title: General poster viewing session III
poster number: 211
session time: 5:45 p.m. – 6:00 p.m. ET
Location: Exhibit Hall ePoster Hub, Monitor 21

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class muscle activators and breakthrough muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or or in decline. As a leader in muscle biology and the mechanics of muscle performance, the company develops small molecule drug candidates specifically designed to impact muscle function and contractility. Cytokinetics is preparing a US NDA submission of mecarbil omecamtiv, its new cardiac muscle activator, following positive results from GALACTIC-HF, a large international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second phase 3 clinical trial of mecarbil omecamtiv. Cytokinetics also develops to affirm, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathy (HCM). The company announced the first positive results of cohorts 1 and 2 of REDWOOD-HCM, a phase 2 clinical trial of to affirm in patients with obstructive HCM. Cytokinetics plans to start a phase 3 clinical trial of to affirm in patients with obstructive HCM in the fourth quarter of 2021. Cytokinetics also develops relative, a rapid skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with ALS. Cytokinetics continues its more than 20-year history of pioneering innovation in muscle biology and related pharmacology focused on muscle dysfunction diseases and muscle weakness states.

For more information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-looking statements

This press release contains forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intention or obligation to update these forward-looking statements and claims the protection of the safe harbor of law for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to one of our other clinical trials, statements relating to the potential benefits of mecarbil omecamtiv, to affirm, or one of our other drug candidates. the research and development activities of Cytokinetics; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of other Cytokinetics drug candidates. These statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in development, testing, regulatory approvals for the initiation of testing, development or sale of products or the manufacture or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have undesirable side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may not be able to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics drug candidates obsolete; and competing products or alternative therapies may be developed by others for the treatment of indications that Cytokinetics’ drug candidates and potential drug candidates may target. For more information regarding these and other risks associated with Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shape logo are registered trademarks of Cytokinetics in the United States and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757